ANAPTYSBIO, INC (ANAB) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 40 days, typically, give or take 11 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q1 FY2026Tue, May 12, 2026after close 42 8-K
Q4 FY2025Tue, Mar 3, 2026after close 62 8-K
Q3 FY2025Tue, Nov 4, 2025after close 35 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Mon, May 5, 2025after close 35 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K
Q3 FY2024Tue, Nov 5, 2024after close 36 8-K

What they guided beta

Q3 FY2026 "Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak monotherapy sales guidance of >$2.7 billion 2" exhibit
Q3 FY2026 "Anaptys estimates Sagard will have accrued ~$330 million in royalties and sales milestones through September 30, 2026 and anticipates paydown of the remaining ~$270 million non-recourse debt monetization in calendar H2 2027" exhibit
Q3 FY2026 "Regulatory submission expected in Japan in calendar H1 2027 and in Europe and China in calendar H2 2027" exhibit
Q3 FY2026 "Regulatory decision expected in Europe in calendar H2 2027 o AZUR-2 – pivotal Phase 3 – dostarlimab versus standard of care in untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer" exhibit
Q3 FY2026 "Data expected in 2028 o AZUR-4 – Phase 2 – dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer" exhibit
Q1 FY2026 "Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak sales guidance of >$2.7 billion 2" exhibit
Q1 FY2026 "Anaptys estimates Sagard will have accrued ~$275 million in royalties and sales milestones through Q1 2026 and anticipates paydown of the remaining ~$325 million non-recourse debt monetization by the end of Q2 2027 3" exhibit
Q1 FY2026 "Data expected in H2 2026; U.S. FDA Breakthrough Therapy Designation" exhibit
Q1 FY2026 "Data expected in 2028 o AZUR-4 – Phase 2 – dostarlimab plus chemotherapy versus standard of care (chemotherapy) in untreated stage III MMRp/MSS resectable colon cancer" exhibit
Q1 FY2026 "Data expected in Q4 2026 o JADE – pivotal Phase 3 – dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 CPS≥1) post chemoradiation" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ANAB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ANAB

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ANAB earnings date badge

HTML

<a href="https://veritasdata.dev/company/ANAB/"><img src="https://veritasdata.dev/embed/ANAB.svg" alt="ANAB earnings date" width="240" height="56"></a>

Markdown

[![ANAB earnings date](https://veritasdata.dev/embed/ANAB.svg)](https://veritasdata.dev/company/ANAB/)

Script

<script async src="https://veritasdata.dev/embed/ANAB.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ANAB"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.